Combining gains in health-related knowledge of Alzheimer’s disease and its application for both genders, reductions in mortality between 1970 and 2000 yielded additional life-years with an end of century value… [ Get More Details ]
It is imperative to weigh costs of implementing new technologies for predicting onset of Alzheimer’s disease through biomarkers and delaying onset earlier against the potential benefits of improving health. Overall… [ Get More Details ]
Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of… [ Get More Details ]
Studies by the National Center for Complementary and Alternative Medicine (NCCAM) at NIH are looking at the neuroprotective qualities of diets rich in B vitamins and antioxidant phytochemicals. These nutrients… [ Get More Details ]
A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.
[ Get More Details ]